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Possible harms of oseltamivir-a call for urgent action
Oseltamivir is a successful drug: between July, 2004, and June, 2009, more than 11·5 million new prescriptions were issued in the USA, and nearly all infl uenza pandemic plans recom mend antiviral drugs as a mainstay of con tainment on a population basis and treatment on an individual basis, with oseltamivir preferred because of ease of administration and storage. Because 75% of the world production of oseltamivir has been used in Japan, 1 this is where to look for any serious harms the drug might cause.
Since 2005, the Japanese Ministry of Health, Labour, and Welfare has funded two prospective cohort studies, and subsequently advised against oseltamivir's use in children and adolescents aged 10-19 years. The fi rst study was in 2846 children in the winter of 2005-06. This study found evidence of unusual behaviour in recipient children within the fi rst day of infection. 1 The second, larger (>10 000 children) cohort study done the following winter failed to fi nd any positive association. However, the analysis was criticised. 1 A detailed independent review of eight serious cases concluded that three sudden deaths during sleep and two near-deaths, as well as two deaths from accidents resulting from abnormal behaviour in older children and adolescents shortly after taking oseltamivir, were probably related to the central depressant action of oseltamivir. 2 As part of updating our 2006 Cochrane review on neuraminidase inhibitors, 3 we are assessing possible harms, and fi rst examined the randomised controlled trials (RCTs). These trials most commonly reported vomiting in adolescents (risk diff erence 0·05, 95% CI 0·02-0·09, number needed to harm 20) 4 and nausea in healthy adults (odds ratio 1·79, 95% CI 1·10-2·93), but no behavioural disturbances or deaths. 3 We looked for harm data outside RCT evidence, submitting a Freedom of Information Act request to the US Food and Drug Administration (FDA) for all harms data in their possession. We received Adverse Event Reporting System (AERS) data from 1999, supplementing the freely accessible FDA AERS data since 2004. 5, 6 The FDA dataset includes 2275 initial adverse event reports from postmarketing surveillance generated worldwide from December, 1999, to July, 2009 (the date of granting our request). Breakdown by setting and even country is diffi cult, because most reports do not indicate these variables and the only date consistently recorded is the date the FDA received the report (which could be several months or even years after the event). The data do not allow standardisation by doses sold or by level of circulating infl uenza, which prevents estimates of reporting rates or seasonal trends. Despite these limitations, many (607/1781, 34%) serious harms were reported in people younger than 20 years. Abnormal behaviour, convulsion, delirium, and hallucinations were more common in the young, while other adverse eff ects (diarrhoea, headache, nausea, loss of consciousness, pyrexia, and vomiting) were not. The most common globally reported potential harms (those which generated at least 50 reports) for oseltamivir are shown in the table.
Since July, 2005, the reporting country was identifi ed in 99·6% of reports. The US reporting rate of adverse events was 0·43 per 10 000 total oseltamivir prescription counts from July, 2005, to March, 2009. However, the FDA AERS data were not of suffi cient quality to answer our study question. For example, adverse events listed for each report were given in alphabetical order, not in order of importance. Information about the patient's setting, symptoms, and timing of the event were often insuffi ciently precise, missing, or absent, which made interpretation of reports impossible. Reports of delirium and confusion could be caused by oseltamivir in children and adolescents. But they could equally be a manifestation of a high temperature due to infl uenza or infl uenza-like illness. 7 Finally, national pandemic stockpiling as well as personal stockpiling indicates that neither sales nor even prescription data might equate with exposure to the drug. 8 Despite these inadequate data, the consistent reports of potential serious harms in adolescents, and the projected future heavy use of oseltamivir, make it imperative to quickly establish large multicentre studies to test any possible associations. The choice of design might prove controversial. Ethical concerns or a supposed rare incidence suggest a case-control design. But if the best estimates from Japan are reliable (a 3% incidence in children using oseltamivir for behavioural changes within a few days-estimates that beg the question of why registration trials did not pick them up), RCTs would be the best. Whichever way, we are running out of time to fi nd answers.
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